Literature DB >> 11561766

Growth inhibition and growth stimulation by estradiol of estrogen receptor transfected human breast epithelial cell lines involve different pathways.

B K Lundholt1, P Briand, A E Lykkesfeldt.   

Abstract

Epidermal growth factor (EGF) and estradiol (E2) are important mitogens in breast epithelial cells, and expression of epidermal growth factor receptor (EGFR) and estrogen receptor (ER) is often inversely correlated in human breast cancer cells. Stable transfection of ER-negative cells with ER cDNA is not sufficient to restore E2-mediated growth stimulation, on the contrary, E2 often inhibits growth of ER-transfected cell lines. In this study we used the ER-transfected human breast epithelial cell lines HMT-3522F9, growth inhibited by E2 in the presence of EGF, and HMT-3522F9/S3B, growth stimulated by E2 in the absence of EGF. In S3B cells, no active MAP kinase could be detected in response to E2, suggesting that signalling through the MAP kinase is not the major pathway in the E2-mediated growth stimulation. Interestingly, a decreased level of active MAP kinase was observed in HMT-3522F9 cells in response to E2, indicating that in these cells cross-talk between the ER and the MAP kinase signalling pathway could be due to the E2-mediated growth inhibition. Moreover, we found that EGF-induced signalling also could be reduced by E2 in S3B cells, suggesting a general mechanism of action by E2 in cells concomitantly expressing ER and EGFR.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11561766     DOI: 10.1023/a:1017977406429

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  14 in total

1.  A kinase inhibitor screen identifies Mcl-1 and Aurora kinase A as novel treatment targets in antiestrogen-resistant breast cancer cells.

Authors:  S Thrane; A M Pedersen; M B H Thomsen; T Kirkegaard; B B Rasmussen; A K Duun-Henriksen; A V Lænkholm; M Bak; A E Lykkesfeldt; C W Yde
Journal:  Oncogene       Date:  2014-11-03       Impact factor: 9.867

Review 2.  Interplay between insulin resistance and estrogen deficiency as co- activators in carcinogenesis.

Authors:  Zsuzsanna Suba
Journal:  Pathol Oncol Res       Date:  2011-10-09       Impact factor: 3.201

3.  TIMP1 overexpression mediates resistance of MCF-7 human breast cancer cells to fulvestrant and down-regulates progesterone receptor expression.

Authors:  Christina Bjerre; Lena Vinther; Kirstine C Belling; Sidse Ø Würtz; Rachita Yadav; Ulrik Lademann; Olga Rigina; Khoa Nguyen Do; Henrik J Ditzel; Anne E Lykkesfeldt; Jun Wang; Henrik Bjørn Nielsen; Nils Brünner; Ramneek Gupta; Anne-Sofie Schrohl; Jan Stenvang
Journal:  Tumour Biol       Date:  2013-07-24

4.  NADH-Cytochrome b5 Reductase 3 Promotes Colonization and Metastasis Formation and Is a Prognostic Marker of Disease-Free and Overall Survival in Estrogen Receptor-Negative Breast Cancer.

Authors:  Rikke R Lund; Rikke Leth-Larsen; Tina Di Caterino; Mikkel G Terp; Jeanette Nissen; Anne-Vibeke Lænkholm; Ole N Jensen; Henrik J Ditzel
Journal:  Mol Cell Proteomics       Date:  2015-09-08       Impact factor: 5.911

5.  Prostate cancer cell proliferation is strongly reduced by the epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 in vitro on human cell lines and primary cultures.

Authors:  Carlo Vicentini; Claudio Festuccia; Giovanni Luca Gravina; Adriano Angelucci; Angelo Marronaro; Mauro Bologna
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-04       Impact factor: 4.553

6.  Redox-modulating agents target NOX2-dependent IKKε oncogenic kinase expression and proliferation in human breast cancer cell lines.

Authors:  Espérance Mukawera; Stefany Chartier; Virginie Williams; Patrick J Pagano; Réjean Lapointe; Nathalie Grandvaux
Journal:  Redox Biol       Date:  2015-06-23       Impact factor: 11.799

7.  Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications.

Authors:  Zsuzsanna Suba
Journal:  Onco Targets Ther       Date:  2014-01-23       Impact factor: 4.147

8.  SRC drives growth of antiestrogen resistant breast cancer cell lines and is a marker for reduced benefit of tamoxifen treatment.

Authors:  Sarah L Larsen; Anne-Vibeke Laenkholm; Anne Katrine Duun-Henriksen; Martin Bak; Anne E Lykkesfeldt; Tove Kirkegaard
Journal:  PLoS One       Date:  2015-02-23       Impact factor: 3.240

9.  New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane.

Authors:  Stine Hole; Astrid M Pedersen; Susanne K Hansen; Johan Lundqvist; Christina W Yde; Anne E Lykkesfeldt
Journal:  Int J Oncol       Date:  2015-01-26       Impact factor: 5.650

10.  Propagation of oestrogen receptor-positive and oestrogen-responsive normal human breast cells in culture.

Authors:  Agla J Fridriksdottir; Jiyoung Kim; René Villadsen; Marie Christine Klitgaard; Branden M Hopkinson; Ole William Petersen; Lone Rønnov-Jessen
Journal:  Nat Commun       Date:  2015-11-13       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.